Supreme Court Agrees to Review Bayer Appeal Regarding Roundup Cancer Lawsuits
The U.S. Supreme Court will review Bayer's appeal to limit Roundup lawsuits using federal preemption. This move could impact 65,000 pending cancer cases.
Insights:
The U.S. Supreme Court agreed on Friday, January 16, 2026, to hear a significant appeal from Bayer AG that could fundamentally reshape the legal landscape for thousands of Roundup-related cancer lawsuits. The justices decided to take up a case initiated by John Durnell john durnell, a plaintiff who alleged he developed non-Hodgkins lymphoma after exposure to the herbicide. This decision follows a ruling by the Missouri Court of Appeals, which had upheld a $1.25 million verdict awarded to John Durnellby a jury in St. Louis.
Following the announcement of the Court's review, shares of Bayer AG ADR rose by nearly 5 percent. The company is currently defending itself against approximately 65,000 pending lawsuits in state and federal courts across the US 
US. Bill Anderson bill anderson, the CEO of Bayer AG, described the court's decision as an important step in the company's multi-pronged strategy to significantly contain this litigation. Bayer AGoriginally acquired the product line through its $63 billion purchase of Monsanto in 2018.
US. Bill Anderson bill anderson, the CEO of Bayer AG, described the court's decision as an important step in the company's multi-pronged strategy to significantly contain this litigation. Bayer AGoriginally acquired the product line through its $63 billion purchase of Monsanto in 2018.
